Human monoclonal antibody-based therapy in the treatment of invasive candidiasis

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Bugli, Francesca ^a   Cacaci, Margherita ^a   Martini, Cecilia ^a   Torelli, Riccardo ^a   Posteraro, Brunella ^a   Sanguinetti, Maurizio ^a   Paroni Sterbini, Francesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; EFUNGUMAB; FLUCONAZOLE; HEAT SHOCK PROTEIN 90; MONOCLONAL ANTIBODY; ANTIFUNGAL AGENT; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; BACKACHE; BATCH FERMENTATION; CYTOKINE RELEASE SYNDROME; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GOOD MANUFACTURING PRACTICE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOREGULATION; INVASIVE CANDIDIASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; CANDIDIASIS, INVASIVE; DRUG ANTAGONISM;

ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; RECOMBINANT PROTEINS;

EID: 84880177413     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/403121     Document Type: Review

References (59)

1. Marasco W. A., Sui J., The growth and potential of human antiviral monoclonal antibody therapeutics. Nature Biotechnology 2007 25 12 1421 1434 2-s2.0-36849087921 10.1038/nbt1363 (Pubitemid 350233138)
2. Raff H. V., Siscoe P. J., Wolff E. A., Maloney G., Shuford W., Human monoclonal antibodies to group B streptococcus. Reactivity and in vivo protection against multiple serotypes. Journal of Experimental Medicine 1988 168 3 905 917 2-s2.0-0023719316
3. Fabrizio K., Manix C., Tian H., van Rooijen N., Pirofski L.-A., The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages. Vaccine 2010 28 47 7542 7550 2-s2.0-77958197452 10.1016/j.vaccine.2010.08.061
4. Casadevall A., Dadachova E., Pirofski L.-A., Passive antibody therapy for infectious diseases. Nature Reviews Microbiology 2004 2 9 695 703 2-s2.0-4444342539 10.1038/nrmicro974 (Pubitemid 39200062)
5. Keller M. A., Stiehm E. R., Passive immunity in prevention and treatment of infectious diseases. Clinical Microbiology Reviews 2000 13 4 602 614 2-s2.0-0033793926 10.1128/CMR.13.4.602-614.2000
6. Martin-Mateos M. A., Monoclonal antibodies in pediatrics: use in prevention and treatment. Allergologia et Immunopathologia 2007 35 4 145 150 10.1157/13108225 (Pubitemid 47434992)
7. Chames P., van Regenmortel M., Weiss E., Baty D., Therapeutic antibodies: successes, limitations and hopes for the future. British Journal of Pharmacology 2009 157 2 220 233 2-s2.0-62149129236 10.1111/j.1476-5381.2009. 00190.x
8. Maggon K., Monoclonal antibody "gold rush" Current Medicinal Chemistry 2007 14 18 1978 1987 2-s2.0-34547696982 10.2174/092986707781368504 (Pubitemid 47209108)
9. Bugli F., Graffeo R., Paroni Sterbini F., Torelli R., Masucci L., Sali M., Grasso A., Rufini S., Ricci E., Fadda G., Pescatori M., Monoclonal antibody fragment from combinatorial phage display library neutralizes alpha-latrotoxin activity and abolishes black widow spider venom lethality, in mice. Toxicon 2008 51 4 547 554 10.1016/j.toxicon.2007.11.014
10. Casadevall A., Pirofski L.-A., A reappraisal of humoral immunity based on mechanisms of antibody- mediated protection against intracellular pathogens. Advances in Immunology 2006 91 1 44 2-s2.0-33747821468 10.1016/S0065-2776(06) 91001-3 (Pubitemid 44286993)
11. Levitz S. M., Overview of host defenses in fungal infections. Clinical Infectious Diseases 1992 14 supplement 1 S37 S42 2-s2.0-0026573544
12. Cheng S. C., Joosten L. A., Kullberg B. J., Netea M. G., Interplay between Candida albicans and the mammalian innate host defense. Infection and Immunity 2012 80 4 1304 1313 10.1128/IAI.06146-11
13. Casadevall A., Feldmesser M., Pirofski L.-A., Induced humoral immunity and vaccination against major human fungal pathogens. Current Opinion in Microbiology 2002 5 4 386 391 2-s2.0-0036345760 10.1016/S1369-5274(02)00337-5
14. Cassone A., de Bernardis F., Torososantucci A., An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis. Current Molecular Medicine 2005 5 4 377 382 2-s2.0-20544441226 10.2174/1566524054022549 (Pubitemid 40846918)
15. Polonelli L., Casadevall A., Han Y., Bernardis F., Kirkland T. N., Matthews R. C., Adrian D., Boccanera M., Burnie J. P., Cassone A., Conti S., Cutler J. E., Frazzi R., Gregory C., Hodgetts S., Illidge C., Magliani W., Rigg G., Santoni G., The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections. Medical Mycology 2000 38 supplement 1 281 292 2-s2.0-0034511320 (Pubitemid 32094076)
16. Mourad S., Friedman L., Active immunization of mice against Candida albicans. Proceedings of the Society for Experimental Biology and Medicine 1961 106 570 572 2-s2.0-0001267646
17. Pearsall N. N., Adams B. L., Bunni R., Immunologic responses to Candida albicans. III. Effects of passive transfer of lymphoid cells or serum on murine candidiasis. Journal of Immunology 1978 120 4 1176 1180 2-s2.0-0017884003 (Pubitemid 8343817)
18. Cabezas J., Albaina O., Montañez D., Sevilla M. J., Moragues M. D., Pontón J., Potential of anti-candida antibodies in immunoprophylaxis. Immunotherapy 2010 2 2 171 183 2-s2.0-77953440739 10.2217/imt.09.76
19. Matthews R. C., Rigg G., Hodgetts S., Carter T., Chapman C., Gregory C., Illidge C., Burnie J., Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrobial Agents and Chemotherapy 2003 47 7 2208 2216 2-s2.0-0037636527 10.1128/AAC.47.7.2208-2216. 2003 (Pubitemid 36753574)
20. Hodgetts S., Nooney L., Al-Akeel R., Curry A., Awad S., Matthews R., Burnie J., Efungumab and caspofungin: pre-clinical data supporting synergy. Journal of Antimicrobial Chemotherapy 2008 61 5 1132 1139 2-s2.0-42149195969 10.1093/jac/dkn075 (Pubitemid 351524461)
21. Louie A., Stein D. S., Zack J. Z., Liu W., Conde H., Fregeau C., VanScoy B. D., Drusano G. L., Dose range evaluation of mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis. Antimicrobial Agents and Chemotherapy 2011 55 7 3295 3304 2-s2.0-79959256586 10.1128/AAC.01324-10
22. Richie D. L., Ghannoum M. A., Isham N., Thompson K. V., Ryder N. S., Nonspecific effect of Mycograb on amphotericin B MIC. Antimicrobial Agents and Chemotherapy 2012 56 7 3963 3964 10.1128/AAC.00435-12
23. Larsen R. A., Pappas P. G., Perfect J., Aberg J. A., Casadevall A., Cloud G. A., James R., Filler S., Dismukes W. E., Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrobial Agents and Chemotherapy 2005 49 3 952 958 2-s2.0-14744279814 10.1128/AAC.49.3.952-958.2005 (Pubitemid 40327709)
24. Andes D., Optimizing antifungal choice and administration. Current Medical Research and Opinion 2013 29 supplement 4 13 18
25. Pfaller M. A., Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. American Journal of Medicine 2012 125 supplement 1 S3 S13 10.1016/j.amjmed.2011.11.001
26. Kohler G., Milstein C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975 256 5517 495 497 2-s2.0-0016756272
27. Ponton J., Marot-Leblond A., Ezkurra P. A., Barturen B., Robert R., Senet J. M., Characterization of Candida albicans cell wall antigens with monoclonal antibodies. Infection and Immunity 1993 61 11 4842 4847 2-s2.0-0027485532 (Pubitemid 23320543)
28. LaJean Chaffin W., Morrow K. J. Jr., Two screening methods show different antigen recognition patterns for four monoclonal antibodies to Candida albicans cell surface. Immunology Letters 1989 22 1 7 11 2-s2.0-0024340774 (Pubitemid 19191469)
29. Brena S., Omaetxebarría M. J., Elguezabal N., Cabezas J., Moragues M. D., Pontón J., Fungicidal monoclonal antibody C7 binds to Candida albicans Als3. Infection and Immunity 2007 75 7 3680 3682 2-s2.0-34447261214 10.1128/IAI.01840-06 (Pubitemid 47040972)
30. Sevilla M. J., Robledo B., Rementeria A., Moragues M. D., Pontón J., A fungicidal monoclonal antibody protects against murine invasive candidiasis. Infection and Immunity 2006 74 5 3042 3045 2-s2.0-33646355928 10.1128/IAI.74.5.3042-3045.2006 (Pubitemid 43673020)
31. Magliani W., Conti S., de Bernardis F., Gerloni M., Bertolotti D., Mozzoni P., Cassone A., Polonelli L., Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nature Biotechnology 1997 15 2 155 158 2-s2.0-0031044651 (Pubitemid 27081781)
32. Burnie J. P., Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with Hsp90 antibodies. International Application no. PCT/GB2001/001195, World Intellectual Property Organization(WIPO), 2001, http://patentscope.wipo.int/search/en/detail.jsf? docId=WO2001076627&recNum=116&maxRec=117&office=&prevFilter= &sortOption=&queryString=%28ET%2Fhsp90%29%2520&tab=PCTDescription
33. Matthews R. C., Burnie J. P., Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 2004 22 7 865 871 2-s2.0-0842281502 10.1016/j.vaccine.2003.11.032 (Pubitemid 38177387)
34. Ferreira R. P., Yu B., Niki Y., Armstrong D., Detection of Candida antigenuria in disseminated candidiasis by immunoblotting. Journal of Clinical Microbiology 1990 28 5 1075 1078 2-s2.0-0025332494 (Pubitemid 20141232)
35. Cowen L. E., Singh S. D., Köhler J. R., Collins C., Zaas A. K., Schell W. A., Aziz H., Mylonakis E., Perfect J. R., Whitesell L., Lindquist S., Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proceedings of the National Academy of Sciences of the United States of America 2009 106 8 2818 2823 2-s2.0-62449104891 10.1073/pnas.0813394106
36. Cowen L. E., Lindquist S., Cell biology: Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005 309 5744 2185 2189 2-s2.0-25844530060 10.1126/science.1118370 (Pubitemid 41396062)
37. Joly A.-L., Wettstein G., Mignot G., Ghiringhelli F., Garrido C., Dual role of heat shock proteins as regulators of apoptosis and innate immunity. Journal of Innate Immunity 2010 2 3 238 247 2-s2.0-77953446392 10.1159/000296508
38. Porsius J. C., van Vliet H. J. A., van Zeijl J. H., Goessens W. H. F., Michel M. F., Detection of an antibody response in immunocompetent patients with systemic candidiasis or Candida albicans colonisation. European Journal of Clinical Microbiology and Infectious Diseases 1990 9 5 352 355 2-s2.0-0025310093 (Pubitemid 20175572)
39. Matthews R., Smith D., Midgley J., Burnie J., Clark I., Conolly M., Gazzard B., Candida and AIDS: evidence for protective antibody. The Lancet 1988 2 8605 263 266 2-s2.0-0023683918
40. Weis C., Kappe R., Sonntag H.-G., Western blot analysis of the immune response to Candida albicans antigens in 391 long-term intensive care patients. Mycoses 1997 40 5-6 153 157 2-s2.0-0031461202 (Pubitemid 28018485)
41. Matthews R. C., Burnie J. P., Tabaqchali S., Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. Journal of Clinical Microbiology 1987 25 2 230 237 2-s2.0-0023084890 (Pubitemid 17232409)
42. Raška M., Běláková J., Wudattu N. K., Kafková L., Růžičková K., Š ebestová M., Kolář Z., Weigl E., Comparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis. Folia Microbiologica 2005 50 1 77 82 2-s2.0-19444374263 (Pubitemid 40722166)
43. Wang G., Sun M., Fang J., Yang Q., Tong H., Wang L., Protective immune responses against systemic candidiasis mediated by phage-displayed specific epitope of Candida albicans heat shock protein 90 in C57BL/6J mice. Vaccine 2006 24 35-36 6065 6073 2-s2.0-33747031173 10.1016/j.vaccine.2006.05.022 (Pubitemid 44209125)
44. Casadevall A., Antibody immunity and invasive fungal infections. Infection and Immunity 1995 63 11 4211 4218 2-s2.0-0028866195
45. Bugli F., Posteraro B., Papi M., Torelli R., Maiorana A., Paroni Sterbini F., Posteraro P., Sanguinetti M., de Spirito M., In vitro interaction between alginate lyase and amphotericin B against Aspergillus fumigatus biofilm determined by different methods. Antimicrobial Agents and Chemotherapy 2013 57 3 1275 1282 10.1128/AAC.01875-12
46. Pachl J., Svododa P., Jacobs F., Vandewoude K., van der Hoven B., Spronk P., Masterson G., Malbrain M., Aoun M., Garbino J., Takala J., Drgona L., Burnie J., Matthews R., A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clinical Infectious Diseases 2006 42 10 1404 1413 2-s2.0-33646455866 10.1086/503428
47. Krenova Z., Pavelka Z., Lokaj P., Skotakova J., Kocmanova I., Teyschl O., Kren L., Mudry P., Sterba J., Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-hodgkin lymphoma using efungumab and amphotericin B colloid dispersion. Journal of Pediatric Hematology/Oncology 2010 32 2 128 130 2-s2.0-77949446523 10.1097/MPH.0b013e3181cb49a8
48. Sutherland A., Ellis D., Treatment of a critically ill child with disseminated Candida glabrata with a recombinant human antibody specific for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin, and voriconazole. Pediatric Critical Care Medicine 2008 9 4 e23 e25 2-s2.0-61749084385 10.1097/PCC.0b013e31817286e8
49. Rowlands H. E., Morris K., Graham C., Human recombinant antibody against Candida. Pediatric Infectious Disease Journal 2006 25 10 959 960 2-s2.0-33749435589 10.1097/01.inf.0000237922.28863.ab (Pubitemid 44510601)
50. Falagas M. E., Ntziora F., Betsi G. I., Samonis G., Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials. International Journal of Antimicrobial Agents 2007 29 2 136 143 2-s2.0-33846062480 10.1016/j.ijantimicag.2006.09.018 (Pubitemid 46073679)
51. Heitman J., Cell biology. A fungal Achilles' heel. Science 2005 309 5744 2175 2176 2-s2.0-25844450827 10.1126/science.1119321 (Pubitemid 41396059)
52. Rigg G. P., Matthews R. C., Donohoe M. S., Aurograb shows broad spectrum synergy with vancomycin against MRSA and VISA (vancomycin-intermediate) strains of Staphylococcus aureus. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC '02) September 2002 San Diego, Calif, USA. abstract E-1645
53. Nooney L., Matthews R. C., Burnie J. P., Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagnostic Microbiology and Infectious Disease 2005 51 1 19 29 2-s2.0-11144335859 10.1016/j. diagmicrobio.2004.08.013 (Pubitemid 40040564)
54. Burioni R., Bugli F., Mancini N., Rosa D., Di Campli C., Moroncini G., Manzin A., Abrignani S., Varaldo P. E., Clementi M., Fadda G., Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology 2001 288 1 29 35 2-s2.0-17944375718 10.1006/viro.2001.1014 (Pubitemid 32846471)
55. Pitarch A., Jiménez A., Nombela C., Gil C., Decoding seroligical response to Candida cell wall immunome into novel diagnostic, prognostic, and therapeutic candidates for systemic candidiasis by proteomic and bioinformatic analyses. Molecular and Cellular Proteomics 2006 5 1 79 96 2-s2.0-31644437049 10.1074/mcp.M500243-MCP200 (Pubitemid 43169343)
56. Bugli F., Mancini N., Kang C.-Y., Di Campli C., Grieco A., Manzin A., Gabrielli A., Gasbarrini A., Fadda G., Varaldo P. E., Clementi M., Burioni R., Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. Journal of Virology 2001 75 20 9986 9990 2-s2.0-0034807355 10.1128/JVI.75.20.9986-9990.2001 (Pubitemid 32900134)
57. Zhang D., Mao Y., Cao Q., Xiong L., Wen J., Chen R., Zhu J., Generation and characterization of a novel recombinant antibody against LMP1-TES1 of Epstein-Barr virus isolated by phage display. Viruses 2013 5 4 1131 1142 10.3390/v5041131
58. Solforosi L., Mancini N., Canducci F., Clementi N., Sautto G. A., Diotti R. A., Clementi M., Burioni R., A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. New Microbiologica 2012 35 3 289 294
59. Meyer T., Schirrmann T., Frenzel A., Miethe S., Stratmann-Selke J., Gerlach G. F., Strutzberg-Minder K., Dübel S., Hust M., Identification of immunogenic proteins and generation of antibodies against Salmonella Typhimurium using phage display. BMC Biotechnology 2012 12 article 29